Rigel Pharmaceuticals Q1 2024 GAAP EPS $(0.05) Misses $(0.03) Estimate, Sales $29.534M Miss $31.284M Estimate
Rigel Pharmaceuticals Q1 2024 GAAP EPS $(0.05) Misses $(0.03) Estimate, Sales $29.534M Miss $31.284M Estimate
銳傑製藥2024年第一季度GAAP每股收益美元（0.05）未達到預期（0.03），銷售額爲2953.4萬美元，低於3128.4萬美元的預期
Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.03) by 66.67 percent. This is a 37.5 percent increase over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $29.534 million which missed the analyst consensus estimate of $31.284 million by 5.59 percent. This is a 13.29 percent increase over sales of $26.070 million the same period last year.
銳傑製藥（納斯達克股票代碼：RIGL）公佈的季度虧損爲每股0.05美元，比分析師普遍預期的0.03美元（0.03美元）低66.67％。這比去年同期每股虧損0.08美元（0.08）增長了37.5％。該公司公佈的季度銷售額爲2953.4萬美元，比分析師普遍預期的3128.4萬美元低5.59％。這比去年同期的260.7億美元銷售額增長了13.29％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。